SCHEMBL1665229

SCHEMBL1665229

CCOC(=O)c1cc(C)[nH]n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.58
HCAR2 Q8TDS4 1/20 0.58
KMT2A Q03164 1/20 0.55
L3MBTL1 Q9Y468 2/20 0.54
NPSR1 Q6W5P4 1/20 0.54
PDE4D Q08499 1/20 0.53
POLB P06746 1/20 0.51
TP53 P04637 1/20 0.50
THRB P10828 1/20 0.50
CYP1A2 P05177 1/20 0.50
ALDH1A1 P00352 2/20 0.48
ALPL P05186 2/20 0.47
MAPT P10636 2/20 0.46
CYP3A4 P08684 1/20 0.46
ALPI P09923 1/20 0.46
ALPG P10696 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
LMNA P02545 1/20 0.45
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1233899 0.86 HCAR2 (0.64) HCAR2KMT2AL3MBTL1NPSR1PDE4D
SCHEMBL4435867 0.85 KMT2A (0.44) DAOHCAR2KMT2AL3MBTL1NPSR1
SCHEMBL25466120 0.85 HCAR2 (0.50) DAOHCAR2KMT2AL3MBTL1NPSR1
SCHEMBL7705757 0.84 HCAR2 (0.59) HCAR2KMT2AL3MBTL1NPSR1PDE4D
SCHEMBL163302 0.84 KMT2A (0.54) KMT2AL3MBTL1NPSR1PDE4DPOLB
SCHEMBL1423671 0.84 KMT2A (0.54) DAOHCAR2KMT2AL3MBTL1NPSR1
SCHEMBL1007015 0.84 MAPK1 (0.61) KMT2AL3MBTL1NPSR1PDE4DPOLB
SCHEMBL1259028 0.83 HCAR2 (0.66) HCAR2KMT2AL3MBTL1NPSR1PDE4D
SCHEMBL17421721 0.83 HCAR2 (0.51) DAOHCAR2KMT2AL3MBTL1NPSR1
SCHEMBL20525148 0.83 KMT2A (0.50) HCAR2KMT2AL3MBTL1NPSR1PDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 388 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112390757-A Simple synthesis process of 5-methyl-1H-pyrazole-3-ethyl formate 南京哈柏医药科技有限公司 2021-02-23 CN claimed
CN-117024411-B Isoquinoline as HPK1 inhibitor 豪夫迈·罗氏有限公司 2026-05-19 CN disclosed
US-12599676-B2 Cytotoxic imidazo[1,2-A]pyridine compounds and their use in therapy MyricX Pharma Limited (GB) 2026-04-14 US disclosed
US-20260085061-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS SITRYX THERAPEUTICS LIMITED (GB) 2026-03-26 US disclosed
EP-4709725-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF Progentos Therapeutics, Inc. (US) 2026-03-18 EP disclosed
US-12577247-B2 Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2A receptor and adenosine 2B receptor antagonist Bugworks Research, Inc. (US) 2026-03-17 US disclosed
EP-4705308-A1 EGFR INHIBITORS FOR TREATING DISEASE Blossomhill Therapeutics, Inc. (US) 2026-03-11 EP disclosed
US-20260049075-A1 CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY MYRICX PHARMA LTD (GB) 2026-02-19 US disclosed
US-20260048136-A1 CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY MYRICX PHARMA LTD (GB) 2026-02-19 US disclosed
US-12545662-B2 MK2 inhibitors and uses thereof XINTHERA, INC. (US) 2026-02-10 US disclosed
US-20050130989-A1 N-arylheteroaromatic products compositions containing them and use thereof AVENTIS PHARMA S. A. (FR) 2005-06-16 US disclosed
EP-1531822-A1 1-ARYL-4-SUBSTITUTED PIPERAZINE DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS Chemocentryx, Inc. (US) 2005-05-25 EP disclosed
EP-1466912-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2004-10-13 EP disclosed
US-20040162282-A1 Substituted piperazines CHEMOCENTRYX, INC. 2004-08-19 US disclosed
US-20040082571-A1 Substituted piperazines CHEMOCENTRYX, INC. (US) 2004-04-29 US disclosed
WO-2004032928-A1 5-SUBSTITUTED 2H-PYRAZONE-3-CARBOXYLIC ACID DERIVATIVES AS ANTILIPOLYTIC AGENTS FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS SUCH AS DYSLIPIDEMIA ARENA PHARMACEUTICALS, INC. (US) 2004-04-22 WO disclosed
WO-2003105853-A1 1-ARYL-4-SUBSTITUTED PIPERAZINES DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS CHEMOCENTRYX, INC. (US) 2003-12-24 WO disclosed
EP-0516982-A1 Process for producing a heterocyclic tertiary amine NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1992-12-09 EP disclosed
US-4389406-A ANTHELMINTICS BEECHAM GROUP LIMITED (GB) 1983-06-21 US disclosed
EP-0041322-A1 m-Pyrazolylamido tetramisole derivatives, compositions thereof, processes for production of such compounds and compositions and their use in treating helminthiasis BEECHAM GROUP PLC (GB) 1981-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260085061-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS PDK1, PDK2, PDK4 DAO 2679/4885HCAR2 1229/4885KMT2A 603/4885
US-20260049075-A1 CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY XPA, FLT3, TPMT DAO 3131/4885HCAR2 4801/4885KMT2A 1570/4885
US-20040082571-A1 Substituted piperazines CCR1, CCR3, CCRL2 DAO 4447/4885HCAR2 31/4885KMT2A 3499/4885
US-20050130989-A1 N-arylheteroaromatic products compositions containing them and use thereof AHR, NQO1, ARNT DAO 2382/4885HCAR2 951/4885KMT2A 1284/4885
US-20260048136-A1 CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY SLC7A1, FLT3, ABL1 DAO 991/4885HCAR2 4162/4885KMT2A 1494/4885
US-12577247-B2 Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2A receptor and adenosine 2B receptor antagonist ADORA1, ADORA3, ADORA2A DAO 252/4885HCAR2 140/4885KMT2A 4008/4885
US-12599676-B2 Cytotoxic imidazo[1,2-A]pyridine compounds and their use in therapy ABL1, FLT3, MTX2 DAO 1577/4885HCAR2 4397/4885KMT2A 1242/4885
US-20040162282-A1 Substituted piperazines CCR1, CCR3, CCRL2 DAO 4447/4885HCAR2 31/4885KMT2A 3499/4885
US-12545662-B2 MK2 inhibitors and uses thereof NR3C2, NR2C2, AGTR2 DAO 563/4885HCAR2 76/4885KMT2A 443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.